Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

Fig. 3

Changes in days of acute headache medication use over Weeks 1–12 in eptinezumab-treated ≥ 75% migraine responders in (A) PROMISE-1 and (B) PROMISE-2 and in ≥ 50–< 75% migraine responders in (C) PROMISE-1 and (D) PROMISE-2. Analyses for each medication are limited to patients who used that medication during the 28-day baseline period. A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. CM, chronic migraine; EM, episodic migraine; Epti, eptinezumab.

Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us